'Our companies share a commitment to innovation and ALOM has the expertise and resources to scale as anticipated demand for our products grow.' -- Anja Krammer, President of BioPharmX.
Menlo Park, CA (PRWEB) January 21, 2015
BioPharmX Corporation (OTCQB: BPMX), a biotechnology company focused on the development of novel drug delivery products to address unmet needs in large, well-defined and underserved markets, has selected ALOM as its supply chain partner to provide assembly and fulfillment services for products from BioPharmX’s distinctive line of pharmaceutical, over-the-counter and supplement applications.
“We are pleased to embark on this partnership with ALOM, which is known for its quality and process excellence. Strategically, working with ALOM is a good fit for BioPharmX as our companies share a commitment to innovation and ALOM has the expertise and resources to scale as anticipated demand for our products grow,” said Anja Krammer, President of BioPharmX.
ALOM is a trusted provider of global supply chain management operations including procurement, inventory management, e-commerce, assembly, print management, digital media duplication, fulfillment, and advanced IT system development and integration. As a mid-market company, ALOM supports its clients’ international expansion from 16 locations globally.
“We at ALOM are committed to delivering our clients’ products and services impeccably,” said ALOM President and CEO Hannah Kain. “By delivering health and wellness products flawlessly, we help uphold our clients’ commitment toward providing relief and restoring well-being while ensuring a stellar customer experience. We pride ourselves on providing innovative supply chain solutions for our clients, and we are thrilled to be adding BioPharmX to our client list as one more company that is an innovative leader in its industry.”
ALOM is FDA registered and holds numerous quality certifications, including ISO 9001 certification, as well as ISO 13485 for medical devices and services.
About BioPharmX Corporation
BioPharmX Corporation (OTCQB: BPMX) is a Silicon Valley-based biotechnology company, which seeks to provide innovative products through unique, proprietary platform technologies for prescription, over-the-counter (“OTC”), and supplement applications in the fast-growing health and wellness markets, including women’s health, dermatology, and otolaryngology (ears, nose & throat). To learn more about BioPharmX, visit http://www.BioPharmX.com.
ALOM is a global leader in supply chain management, serving as a partner to its clients in the technology, automotive, medical, telecommunications, pharmaceutical, and utility/energy sectors. Its expert team of strategists, engineers, and specialists operate in ALOM’s headquarters and its 15 affiliated facilities around the world. ALOM is proud to deliver its clients’ products and services impeccably, enrich the customer experience, and uphold their brand reputations. http://www.alom.com
Statements in this news release relating to the business of BioPharmX, which are not historical facts, are "forward-looking statements". These forward-looking statements may be identified by words such as “expect,” “anticipate,” “believe,” or similar expressions that are intended to identify such forward-looking statements. All forward-looking statements are expressly qualified in their entirety by this cautionary statement and the risks and other factors detailed in the company’s filings with the Securities and Exchange Commission (SEC). Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements included in this news release are made only as of the date hereof and the company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.
BioPharmX is a pending trademark of BioPharmX, Inc. All other brand and product names are trademarks or registered trademarks of their respective holders.